Literature DB >> 358884

Gentamicin in 1978.

G B Appel, H C Neu.   

Abstract

For a decade gentamicin has been used extensively because of its antimicrobial efficacy and the relatively low prevalence of clinical toxicity. Recently the more frequent appearance of resistant organisms, reports of increased nephrotoxicity and ototoxicity, and the development of newer aminoglycoside antibiotics have raised doubts about the continued use of this agent. This paper reassesses the role of gentamicin. It is clear that an appreciation of the pharmacokinetics and the clinical use of gentamicin as well as an understanding of the patterns of toxicity in animals and humans can lead to more efficient treatment with this antimicrobial agent. Despite ample competition from a number of newer aminoglycoside antibiotics, gentamicin will probably continue to be used widely in the near future.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 358884     DOI: 10.7326/0003-4819-89-4-528

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  24 in total

1.  Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation.

Authors:  Hélène Servais; Yves Jossin; Françoise Van Bambeke; Paul M Tulkens; Marie-Paule Mingeot-Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function.

Authors:  A Lau; M Lee; S Flascha; R Prasad; R Sharifi
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

3.  Latex agglutination inhibition card test for gentamicin assay: clinical evaluation and comparison with radioimmunoassay and bioassay.

Authors:  H C Standiford; D Bernstein; H C Nipper; E Caplan; B Tatem; J S Hall; J Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

4.  Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.

Authors:  J M Gatell; J G San Miguel; L Zamora; V Araujo; M Bonet; M Bohé; M T Jimenez de Anta; M Farré; M Elena; A Ballesta; J L Marin
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

5.  A rapid urine test for early detection of kidney injury.

Authors:  Vishal S Vaidya; Glen M Ford; Sushrut S Waikar; Yizhuo Wang; Matthew B Clement; Victoria Ramirez; Warren E Glaab; Sean P Troth; Frank D Sistare; Walter C Prozialeck; Joshua R Edwards; Norma A Bobadilla; Stephen C Mefferd; Joseph V Bonventre
Journal:  Kidney Int       Date:  2009-04-22       Impact factor: 10.612

6.  Urinary alanine aminopeptidase and beta 2-microglobulin as measurements of aminoglycoside-associated renal impairment.

Authors:  B Trollfors; J Bergmark; K Hiesche; R Jagenburg
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

7.  Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats.

Authors:  G Laurent; P Maldague; M B Carlier; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

8.  Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

Authors:  C de Gislain; M Dumas; P d'Athis; J L Lautissier; A Escousse; J Guerrin
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  In vitro interaction of aminoglycosides with beta-lactam penicillins.

Authors:  S M Wallace; L Y Chan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.